Searched for
MOUNJARO ZEPBOUND
Gene therapy for cholesterol: Initial test results cheerA new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in b...- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Diabetes type 2, weight loss treatment can be done under single procedure? Research reveals big health updateDiabetes type 2 treatment: Trial participants either underwent a procedure used to improve blood sugar control in type 2 diabetes called du...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Eli Lilly cuts Zepbound price to widen access for obesity drugEli Lilly has reduced the cost of its popular obesity drug Zepbound for American patients. This move aims to make the treatment more access...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Eli Lilly becomes first drugmaker to hit trillion-dollar m-cap on weight-loss demand boomWall Street estimates the weight-loss drug market to be worth $150 billion by 2030, with Lilly and Novo together controlling the majority o...
- AI treatment for weight-loss: Artificial Intelligence tools help researchers analyze 1,300 medical conditions, right medicinesResearchers analyzed 14 million doctors’ notes and 15 million clinical data entries from more than 135,000 patients with and without diabet...
- Eli Lilly plans to launch experimental weight-loss pill in India, says executiveLilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatid...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- Eli Lilly launches weight-loss drug Mounjaro in India at Rs. 3,500 after drug regulator approvalEli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising obesity and dia...
- Weight-loss drug Mounjaro now in India: What is the price? What are the side effects? Here's all you need to knowEli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling with obesity an...
- Eli Lilly announces $27-billion US expansion: To add 13,000 jobs and new manufacturing sitesEli Lilly & Co has announced a $27-billion expansion of its US manufacturing operations, adding four new sites and creating 13,000 jobs. Th...
- This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults....
- Americans hungry for weight-loss drugs grapple with supply and insurance hurdlesDespite supply chain issues easing, patients seeking weight-loss drugs like Wegovy and Zepbound are turning to cheaper compounded versions ...
- Lilly lifts sales forecast by $3 billion as weight-loss drug powers resultsAnalysts have said the companies will likely split the U.S. market roughly 50-50 by the end of 2024, as Lilly bolsters its manufacturing ca...
- Waiting for a wonder drug? The weight just got longerEli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the dru...
- Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billionExplosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...
- Eli Lilly could launch obesity drug in India next year, CEO saysEli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepboun...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
Load More
